WALDENSTRÖM MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of three drugs targets Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered T-Cells take on tough lymphoma in early trial
Disease control OngoingThis phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for blood cancer patients
Disease control OngoingThis early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug duo shows promise for rare blood cancer
Disease control OngoingThis study tests two oral drugs, pirtobrutinib and venetoclax, in 46 people with Waldenström macroglobulinemia who have already had at least one prior treatment. The goal is to see if the combination can shrink the cancer and improve response rates. Researchers are also tracking …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for rare blood cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called loncastuximab tesirine in 21 people with Waldenström macroglobulinemia, a rare blood cancer, whose disease has not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and lower abnormal protein levels. Partic…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Double attack on lymphoma: antibody plus CAR-T combo shows promise
Disease control OngoingThis study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC